Immune Design (Immune Design) Sloan Ratio % : -53.50% (As of Dec. 2018)

View and export this data going back to 2014. Start your Free Trial

What is Immune Design Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

Immune Design's Sloan Ratio for the quarter that ended in Dec. 2018 was -53.50%.

As of Dec. 2018, Immune Design has a Sloan Ratio of -53.50%, indicating earnings are more likely to be made up of accruals.

Immune Design Sloan Ratio % Historical Data

The historical data trend for Immune Design's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immune Design Sloan Ratio % Chart

Immune Design Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Sloan Ratio %

Get a 7-Day Free Trial

-16.76

-1.05

38.98

5.35

-53.50

Immune Design Quarterly Data
	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18
Sloan Ratio %	Get a 7-Day Free Trial															5.35	-2.60	2.14	-0.26	-53.50

Competitive Comparison of Immune Design's Sloan Ratio %

For the Biotechnology subindustry, Immune Design's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immune Design's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immune Design's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where Immune Design's Sloan Ratio % falls into.

Immune Design Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

Immune Design's Sloan Ratio for the fiscal year that ended in Dec. 2018 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2018 )	-	Cash Flow from Operations (A: Dec. 2018 )
	-	Cash Flow from Investing (A: Dec. 2018 ))	/	Total Assets (A: Dec. 2018 )
	=	(-54.758	-	-51.666
	-	50.925)	/	100.96
	=	-53.50%

Immune Design's Sloan Ratio for the quarter that ended in Dec. 2018 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Dec. 2018 )
	=	(-54.758	-	-51.666
	-	50.925)	/	100.96
	=	-53.50%

Immune Design's Net Income for the trailing twelve months (TTM) ended in Dec. 2018 was -13.3 (Mar. 2018 ) + -13.808 (Jun. 2018 ) + -14.049 (Sep. 2018 ) + -13.601 (Dec. 2018 ) = $-54.76 Mil.
Immune Design's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2018 was -16.383 (Mar. 2018 ) + -10.919 (Jun. 2018 ) + -12.966 (Sep. 2018 ) + -11.398 (Dec. 2018 ) = $-51.67 Mil.
Immune Design's Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2018 was 9.875 (Mar. 2018 ) + 12.046 (Jun. 2018 ) + 8.071 (Sep. 2018 ) + 20.933 (Dec. 2018 ) = $50.93 Mil.

Immune Design (NAS:IMDZ) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Dec. 2018, Immune Design has a Sloan Ratio of -53.50%, indicating earnings are more likely to be made up of accruals.

Immune Design Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of Immune Design's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immune Design (Immune Design) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immune Design Corp (NAS:IMDZ) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1616 Eastlake Avenue East, Suite 310, Seattle, WA, USA, 98102

Website

http://www.immunedesign.com

Immune Design is a clinical-stage immunotherapy company. Its focus is next-generation in vivo methods intended to enable the body's immune system to fight diseases. The company's therapies have a broad potential approach across multiple therapeutic areas. Nevertheless, the company's target is oncology, and it is developing tumor-specific cytotoxic T cells to fight cancer. The main discoveries are CMB305 and G100, immuno-oncology approaches that are believed to address the shortcomings of existing oncological therapies.

Executives

William R Ringo	director
David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Edward Penhoet	director	ONE EMBARCADERO CENTER SUITE 3700, SAN FRANCISCO CA 94111
Susan L. Kelley	director	C/O DECIPHERA PHARMACEUTICALS, INC., 200 SMITH STREET, WALTHAM MA 02451
Carlos V Paya	director, officer: President and CEO	C/O IMMUNE DESIGN CORP., 1616 EASTLAKE AVE. E, SUITE 310, SEATTLE WA 98102
David V Goeddel	10 percent owner, other: Managing Partner	C/O COLUMN GROUP LP, 1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Peter Svennilson	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Tim Kutzkey	10 percent owner, other: Managing Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Ii Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Capital, Lp	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Ponoi Management, Llc	10 percent owner, other: General Partner	1 LETTERMAN DRIVE, BUILDING D, SUITE M-900, SAN FRANCISCO CA 94129
Column Group L P	10 percent owner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Column Group Gp, Lp	10 percent owner, other: General Partner	1700 OWENS STREET, SUITE 500, SAN FRANCISCO CA 94158
Franklin M Berger	director	1000 MARINA BLVD, STE 200, BRISBANE CA 94005